Digital Biomarkers for Clinical Diagnostics Market is expected to reach USD 22.9 billion by 2031

Digital Biomarkers for Clinical Diagnostics Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the digital biomarkers for clinical diagnostics market will expand from USD 6.4 billion in 2026 to USD 22.9 billion in 2031 at a CAGR of 29.0% during the forecast period.

The market is evolving very fast owing to the increasing demand of remote patient monitoring, decentralized clinical trials and data-driven clinical decision-making. The use of digital biomarkers allows the continuous and non-invasive collection of data, which improves the accuracy of the diagnosis and allows early intervention. The development of wearable technologies, mobile health apps and AI-driven analytics are further fueling the growth of the market.

Request a free sample copy or view the report summary: Digital Biomarkers for Clinical Diagnostics Market Report

Digital Biomarkers for Clinical Diagnostics Market Report Highlights

• By Component, the most rapidly growing market is Software and Analytics Platforms due to the growing need to process and analyze large amounts of real-time patient data. There is also a tremendous growth in integration platforms and cloud-based analytics solutions reinforced by the increased demand of scalable and interoperable systems. The scope of services, like deployment, validation, and regulatory support, is broadening because of the intricacy of introducing digital biomarkers into the clinical workflow.

• By Biomarker Type, physiological biomarkers (e.g., heart rate, activity levels, sleep patterns) currently take up a large portion since they are widely used in wearable devices. But behavioral, cognitive biomarkers should increase at the most rapid rate, especially in applications related to neurological and mental health. New digital biomarkers using voice, gait, and pattern of digital interactions are in the offing to be used in the detection of early diseases.

• By Application, the fastest growth is seen in neuro-logy due to its increasing use in the conditions of Alzheimer disease, Parkinson disease and multiple sclerosis. Digital biomarkers allow continuous follow-up of cognitive and motor functions, enhancing the early diagnosis and tracking of the progression of the disease. Other high growth sectors are cardiovascular diseases, respiratory disorders, and mental health. Other expanding uses are metabolic diseases and oncology with the use of digital biomarkers to monitor treatment, track patient compliance, and measure their outcomes.

• By geographical region, North America will have the highest market share because of the high adoption of digital health technologies, the presence of leading technological and healthcare firms, and favorable regulatory initiatives. Further stimulation of the market in the region is introduced by further increased investment in remote monitoring and AI-based diagnostics.

Digital Biomarkers for Clinical Diagnostics Market Growth Drivers and Restraints

Growth Drivers:

• Rising Demand for Remote and Continuous Monitoring: The growing prevalence of chronic diseases and the need for real-time health tracking are driving adoption of digital biomarkers. These tools enable continuous, non-invasive monitoring, improving early detection and clinical outcomes.

• Shift Toward Personalized and Preventive Healthcare: Healthcare systems are increasingly focusing on individualized care approaches. Digital biomarkers provide granular patient-level insights, enabling tailored treatment strategies and proactive disease management.

Restraints:

• Data Privacy and Regulatory Challenges: The use of patient-generated health data raises concerns around data security, privacy, and regulatory compliance. Variability in global regulatory frameworks can slow adoption and commercialization.

• Integration and Validation Complexity: Integrating digital biomarkers into clinical practice requires validation, standardization, and interoperability with existing healthcare systems. The need for clinical evidence and technical expertise can pose barriers, particularly in developing regions.

Digital Biomarkers for Clinical Diagnostics Market Key Development

• Product Launch: In May 2025, AliveCor launched its AI-powered KardiaMobile 6L Max, an advanced personal ECG system featuring enhanced arrhythmia detection and a new KardiaAlert function, which identifies changes in heart rhythm over time and notifies users for early intervention.

Digital Biomarkers for Clinical Diagnostics Market Segmentation

Knowledge Sourcing Intelligence has segmented the Digital Biomarkers for Clinical Diagnostics by biomarker type, technology, application and geography:

Digital Biomarkers for Clinical Diagnostics Market, By Biomarker Type

• Physiological Biomarkers

• Behavioural Biomarkers

• Cognitive Biomarkers

• Digital Phenotypes

Digital Biomarkers for Clinical Diagnostics Market, By Technology

• Artificial Intelligence & Machine Learning

• Data Analytics Platforms

• Cloud Computing

• IoT Integration

Digital Biomarkers for Clinical Diagnostics Market, By Application

• Neurology

• Cardiology

• Oncology

• Mental Health

• Chronic Disease Management

Digital Biomarkers for Clinical Diagnostics Market, By Region

• North America

  • USA

  • Canada

  • Mexico

• South America

  • Brazil

  • Argentina

  • Others

• Europe

  • United Kingdom

  • Germany

  • France

  • Spain

  • Others

• Middle East and Africa

  • Saudi Arabia

  • UAE

  • Others

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Indonesia

  • Thailand

  • Others

Digital Biomarkers for Clinical Diagnostics Market Key Players

• Apple

• Google (Alphabet)

• Fitbit (Google)

• Philips Healthcare

• Medtronic

• Biogen

• Verily Life Sciences

• AliveCor

• Empatica

• Biofourmi